United Therapeutics Corporation Announces Participation at Upcoming Investor ConferencesBusiness Wire • Monday
United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 11/04/26
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/28/26
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial HypertensionBusiness Wire • 10/28/26
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase AuthorizationBusiness Wire • 10/22/26
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026Business Wire • 10/21/26
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production FacilityBusiness Wire • 10/20/26
United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPDBusiness Wire • 10/19/26
Liquidia shares surge 25% as settlement ends United Therapeutics litigationProactive Investors • 10/14/26
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%24/7 Wall Street • 10/14/26
Liquidia And United Therapeutics Settle; But Only One Stock SkyrocketedInvestors Business Daily • 10/14/26
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%Zacks Investment Research • 10/01/26
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For ThursdayBenzinga • 10/01/26
United Therapeutics Stock Rises Following Federal Court Patent Victory Over LiquidiaBenzinga • 10/01/26